Weiss K B, Sullivan S D
Center for Health Services Research, Rush Primary Care Institute, Rush-Presbyterian-St. Luke's Medical Center, Chicago 60612, USA.
J Allergy Clin Immunol. 2001 Jan;107(1):3-8. doi: 10.1067/mai.2001.112262.
As new health care strategies compete with existing ones for limited resources, the health care system and its providers are beginning to turn to health economic analyses to help inform choices in the delivery of care. This 2-part review examines the current health economic literature for asthma and rhinitis. This first installment of the review focuses on studies that characterize the economic burden of asthma and rhinitis and examines how resources are allocated to the care of persons with asthma and rhinitis. In 1998, asthma in the United States accounted for an estimated 12.7 billion dollars annually. Similarly, in 1994, allergic rhinitis was estimated to cost 1.2 billion dollars. Most of the costs for these conditions are attributed to direct medical expenditures, with medications emerging as the single largest cost component. Indirect costs also represent an important social effect. While cost-of-illness studies help to characterize the economic burden, comparative health economic studies evaluate the value of new and existing strategies for clinical care. The second part of this review will explore how comparative studies have contributed to understanding how to best diagnose and treat asthma and allergic rhinitis.
随着新的医疗保健策略与现有策略争夺有限资源，医疗保健系统及其提供者开始转向卫生经济分析，以帮助为医疗服务提供中的选择提供信息。这篇分两部分的综述考察了当前关于哮喘和鼻炎的卫生经济文献。本综述的第一部分重点关注那些描述哮喘和鼻炎经济负担的研究，并考察资源是如何分配给哮喘和鼻炎患者的护理的。1998年，美国哮喘每年估计花费127亿美元。同样，1994年，过敏性鼻炎估计花费12亿美元。这些疾病的大部分费用归因于直接医疗支出，药物成为单一最大的成本组成部分。间接成本也代表着重要的社会影响。虽然疾病成本研究有助于描述经济负担，但比较卫生经济研究评估新的和现有的临床护理策略的价值。本综述的第二部分将探讨比较研究如何有助于理解如何最好地诊断和治疗哮喘及过敏性鼻炎。
